16
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Analysis of circulating microRNAs in patients with repaired Tetralogy of Fallot with and without heart failure

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          MicroRNAs (miRNAs) are a class of regulatory RNAs that regulate gene expression post-transcriptionally. Little, however, is known on the expression profile of circulating miRNAs in Tetralogy of Fallot (TOF) patients late after surgical repair. In this study, we aimed to identify the specific patterns of circulating miRNAs in blood of patients with repaired, non-syndromic TOF and to assess whether these specific miRNAs may be useful to differentiate patients with and without heart failure.

          Methods

          SurePrint™ 8 × 60 K Human v16 miRNA arrays were used to determine miRNA expression profiles in 15 healthy controls and 37 patients after TOF repair of whom 3 had symptomatic right heart failure. The expression levels of selected miRNAs have been validated by quantitative reverse transcription polymerase chain reaction (RT-qPCR). Enrichment analyses of altered miRNA expression were predicted using bioinformatic tools.

          Results

          Compared with healthy controls, a total of 49, 58 and 77 miRNAs were found to be significantly altered in TOF patients (TOF-all), TOF patients with (TOF-HF) and without symptomatic right heart failure (TOF-noHF) (>2.0-fold change, adjusted P < 0.05), respectively. Three miRNAs namely miR-181d-5p, miR-206 and miR-625-5p were validated by RT-qPCR in all TOF groups. The area under the receiver operating characteristic curve (AUC) for miR-181d-5p, miR-206 and miR-625-5p were 0.987, 0.993 and 0.769 in TOF-all and 0.990, 0.994 and 0.749 in TOF-noHF, respectively. Moreover, expression levels of miR-625-5p, miR-1233-3p and miR-421 were lower in TOF-HF compared to TOF-noHF ( P = 0.012).

          Conclusions

          Altered expression levels of circulating miRNAs were found in TOF patients late after surgical repair and are different to those seen in the right ventricular myocardium of infants with TOF. Expression levels of miR-421, miR-1233-3p and miR-625-5p are lower in TOF patients with symptomatic right heart failure and thus may indicate disease progression in these patients.

          Electronic supplementary material

          The online version of this article (doi:10.1186/s12967-017-1255-z) contains supplementary material, which is available to authorized users.

          Related collections

          Most cited references36

          • Record: found
          • Abstract: found
          • Article: not found

          Role of flow-sensitive microRNAs in endothelial dysfunction and atherosclerosis: mechanosensitive athero-miRs.

          Atherosclerosis preferentially occurs in arterial regions exposed to disturbed flow, in part, due to alterations in gene expression. MicroRNAs (miRNAs) are small, noncoding genes that post-transcriptionally regulate gene expression by targeting messenger RNA transcripts. Emerging evidence indicates that alteration of flow conditions regulate expression of miRNAs in endothelial cells both in vitro and in vivo. These flow-sensitive miRNAs, known as mechano-miRs, regulate endothelial gene expression and can regulate endothelial dysfunction and atherosclerosis. MiRNAs such as, miR-10a, miR-19a, miR-23b, miR-17-92, miR-21, miR-663, miR-92a, miR-143/145, miR-101, miR-126, miR-712, miR-205, and miR-155, have been identified as mechano-miRs. Many of these miRNAs were initially identified as flow sensitive in vitro and were later found to play a critical role in endothelial function and atherosclerosis in vivo through either gain-of-function or loss-of-function approaches. The key signaling pathways that are targeted by these mechano-miRs include the endothelial cell cycle, inflammation, apoptosis, and nitric oxide signaling. Furthermore, we have recently shown that the miR-712/205 family, which is upregulated by disturbed flow, contributes to endothelial inflammation and vascular hyperpermeability by targeting tissue inhibitor of metalloproteinase-3, which regulates metalloproteinases and a disintegrin and metalloproteinases. The mechano-miRs that are implicated in atherosclerosis are termed as mechanosensitive athero-miRs and are potential therapeutic targets to prevent or treat atherosclerosis. This review summarizes the current knowledge of mechanosensitive athero-miRs and their role in vascular biology and atherosclerosis. © 2014 American Heart Association, Inc.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Circulating microRNAs as biomarkers and potential paracrine mediators of cardiovascular disease.

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              The insulin-like growth factor 1 receptor induces physiological heart growth via the phosphoinositide 3-kinase(p110alpha) pathway.

              Insulin-like growth factor 1 (IGF1) was considered a potential candidate for the treatment of heart failure. However, some animal studies and clinical trials have questioned whether elevating IGF1 chronically is beneficial. Secondary effects of increased serum IGF1 levels on other tissues may explain these unfavorable results. The aim of the current study was to examine the role of IGF1 in cardiac myocytes in the absence of secondary effects, and to elucidate downstream signaling pathways and transcriptional regulatory effects of the IGF1 receptor (IGF1R). Transgenic mice overexpressing IGF1R in the heart displayed cardiac hypertrophy, which was the result of an increase in myocyte size, and there was no evidence of histopathology. IGF1R transgenics also displayed enhanced systolic function at 3 months of age, and this was maintained at 12-16 months of age. The phosphoinositide 3-kinase (PI3K)-Akt-p70S6K1 pathway was significantly activated in hearts from IGF1R transgenics. Cardiac hypertrophy induced by overexpression of IGF1R was completely blocked by a dominant negative PI3K(p110alpha) mutant, suggesting IGF1R promotes compensated cardiac hypertrophy in a PI3K(p110alpha)-dependent manner. This study suggests that targeting the cardiac IGF1R-PI3K(p110alpha) pathway could be a potential therapeutic strategy for the treatment of heart failure.
                Bookmark

                Author and article information

                Contributors
                +49 6841 16- 26289 , masood@daad-alumni.de
                hgemee@uks.eu
                andreas.keller@ccb.uni-saarland.de
                Hashim.Abdul-Khaliq@uniklinikum-saarland.de
                Tanja.Raedle-Hurst@uniklinikum-saarland.de
                Journal
                J Transl Med
                J Transl Med
                Journal of Translational Medicine
                BioMed Central (London )
                1479-5876
                10 July 2017
                10 July 2017
                2017
                : 15
                : 156
                Affiliations
                [1 ]ISNI 0000 0001 2167 7588, GRID grid.11749.3a, Department of Human Genetics, , Saarland University, ; 66421 Homburg/Saar, Germany
                [2 ]ISNI 0000 0001 2167 7588, GRID grid.11749.3a, Chair for Clinical Bioinformatics, , Saarland University, ; 66041 Saarbruecken, Germany
                [3 ]GRID grid.411937.9, Department of Pediatric Cardiology, , Saarland University Medical Center, ; 66421 Homburg/Saar, Germany
                [4 ]GRID grid.411937.9, Department of Human Genetics, , Saarland University Medical Center, ; Kirrberger Straße 100, 66421 Homburg/Saar, Germany
                Article
                1255
                10.1186/s12967-017-1255-z
                5504636
                28693530
                b02f6353-744d-4c81-988b-a33e31116ce5
                © The Author(s) 2017

                Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

                History
                : 24 March 2017
                : 24 June 2017
                Funding
                Funded by: Fördergemeinschaft Kinderherzen in Bonn
                Funded by: Competence Network for Congenital Heart Defects
                Award ID: 01GI0601 (2014)
                Award Recipient :
                Funded by: German Centre for Cardiovascular Research (DZHK)
                Award ID: 81X2800112 (2015)
                Award Recipient :
                Categories
                Research
                Custom metadata
                © The Author(s) 2017

                Medicine
                microrna,heart failure,congenital heart defects,tetralogy of fallot
                Medicine
                microrna, heart failure, congenital heart defects, tetralogy of fallot

                Comments

                Comment on this article